Genelux (NASDAQ:GNLX) Director Sells $34,920.00 in Stock

Genelux Corporation (NASDAQ:GNLX) Director John Smither sold 12,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $2.91, for a total transaction of $34,920.00. Following the sale, the director directly owned 91,403 shares in the company, valued at approximately $265,982.73. This trade represents a 11.61% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Genelux Price Performance

Shares of NASDAQ:GNLX opened at $2.99 on Friday. The firm has a market capitalization of $134.07 million, a PE ratio of -3.52 and a beta of 0.58. The company has a 50-day moving average price of $2.90 and a two-hundred day moving average price of $2.93. Genelux Corporation has a twelve month low of $2.29 and a twelve month high of $8.53.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Analysts anticipate that Genelux Corporation will post -0.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GNLX. Wall Street Zen downgraded Genelux from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genelux in a research report on Tuesday, April 21st. Finally, Benchmark decreased their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a research note on Friday, March 20th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Institutional Trading of Genelux

A number of large investors have recently modified their holdings of the business. Jefferies Financial Group Inc. bought a new position in shares of Genelux in the fourth quarter worth approximately $48,000. Squarepoint Ops LLC bought a new stake in Genelux during the fourth quarter valued at approximately $52,000. Raymond James Financial Inc. lifted its position in Genelux by 22.6% during the second quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock valued at $83,000 after purchasing an additional 5,333 shares during the last quarter. Marshall Wace LLP purchased a new position in Genelux in the 2nd quarter worth approximately $92,000. Finally, Balyasny Asset Management L.P. purchased a new position in Genelux in the 4th quarter worth approximately $94,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.